Subtype
Astrocytic Tumor
CI-CAN-00001839Explore in graph →
Non-malignant507 active trials2 approved drugs67 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001839Explore in graph →
Clinical trials
1,861 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05183204 | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | completed | Phase 2 | 24 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05635734 | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Cantex PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03174197 |
| Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma |
| completed |
| Phase 1 / Phase 2 |
| 60 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT03277638 | Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) | completed | Phase 1 / Phase 2 | 32 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03657576 | Trial of C134 in Patients With Recurrent GBM(C134-HSV-1) | completed | Phase 1 | 19 | University of Alabama at BirminghamOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04201873 | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | completed | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03739372 | Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma(PNOC008) | completed | N/A | 44 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02761070 | Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III(RE-GEND) | completed | Phase 3 | 146 | Kyorin UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04730869 | Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma | completed | N/A | 18 | Waikato HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03900689 | Social Determinants of Health in Glioblastoma Population | completed | — | 100 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT01339052 | Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma | completed | Phase 2 | 65 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02902757 | FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma | completed | N/A | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03477513 | Personalized Radiation Therapy for GBM | completed | N/A | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05326464 | Tofacitinib in Recurrent GBM Patients | completed | Phase 3 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673666 | GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)(GliomaAI-A23) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673679 | GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4(GliomaAI-A4) | completed | — | 1,372 | Deep Learning Institute of Radiological SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00209989 | Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme | completed | Phase 2 | 27 | Institut Claudius RegaudOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | completed | — | 1 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03115164 | Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics(DIA/DIG) | completed | — | 37 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07635173 | SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas | completed | Phase 1 | 35 | Shenzhen Zhenxing Medical Technology Co., LtdOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03514069 | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | completed | Phase 1 | 60 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03975959 | Memory Perception Assessment in Central/Non-central Nervous System Cancers(PROMESSE) | completed | N/A | 426 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05186064 | Glioblastoma Targeted Treatment Option Maximization by WGS(GLOW) | completed | N/A | 164 | UMC UtrechtOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03630289 | Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM | completed | N/A | 12 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT00906893 | Evaluation of [18F]-FMISO for Non Operated Glioblastoma(MISOGLIO) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04614909 | Study of Pamiparib in Newly Diagnosed and rGBM | completed | Early Phase 1 | 50 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06796335 | Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour | completed | — | 35 | Rigshospitalet, DenmarkOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06625047 | Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy | completed | Phase 4 | 30 | Mayo ClinicOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02631655 | POSitron Emission Imaging Using 18F-FDOPA in Neurooncology(POSEIDON) | completed | N/A | 110 | Centre Antoine LacassagneOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | completed | Phase 2 / Phase 3 | 159 | National Cancer Institute (NCI)NIH | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04817254 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04998864 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients | completed | — | 3 | InSightecINDUSTRY | 2 | Apr 16, 2026 | clinicaltrials |
| NCT03451799 | Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma | completed | Phase 1 | 21 | Jethro HuOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01872221 | Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study(STEMRI) | completed | N/A | 21 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02866747 | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma(STERIMGLI) | completed | Phase 1 / Phase 2 | 108 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04988750 | Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients | completed | N/A | 7 | NaviFUS CorporationINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04446416 | Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients | completed | N/A | 6 | NaviFUS CorporationINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07497373 | A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma(JL15003) | completed | Phase 1 | 17 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06650605 | Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma(CITADEL-123) | completed | Phase 1 | 7 | Theragnostics LtdINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03194971 | NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy | completed | — | 20 | Medical College of WisconsinOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04471844 | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM(EF-32) | completed | N/A | 981 | NovoCure Ltd.INDUSTRY | 11 | Mar 30, 2026 | clinicaltrials |
| NCT07499141 | Use of Fluorescence in Gliomas(UFGAG) | completed | — | 41 | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04019002 | Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma | completed | Phase 1 | 17 | Susan ChangOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02286167 | Glioma Modified Atkins-based Diet in Patients With Glioblastoma(GLAD) | completed | N/A | 25 | Wake Forest University Health SciencesOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03551249 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption | completed | N/A | 20 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials